Preliminary studies indicate that cannabinoids can increase the potency and decrease the minimal required therapeutic dosages of antibacterial agents
The Joint Venture will initially focus on building out an approximate 2,000 square foot facility at Abba’s Pickering cannabis grow facility, to house a cannabis oil extraction operation focused on producing the oils and extracts currently permitted under ACMPR.
The project aims to improve this crop to reduce growers reliance on pesticides and excessive application of fertilizers.
The funding will be used to inform Canadians of the health and safety risks of cannabis use and drug-impaired driving.
In anticipation of California's new testing rules EVIO has invested in additional instrumentation to offer a full suite of testing services including pesticide, microbiological, and expanded cannabinoid potency testing.
This collaborative agreement will focus on researching and developing safer pharmaceutical cannabis-based products and moving these products through clinical trials using FDA guidelines.
The authors of the research also commented on the need for further research stressing that there is a notable lack of studies and a minimal number of the randomized, controlled trials needed to confirm the effectiveness of any treatment.
38% of resident physicians think medical marijuana is a prescribed substance, while 78% do not know what category medical cannabis falls within the Controlled Substance Act.